Provided by Tiger Trade Technology Pte. Ltd.

Oppenheimer

85.85
-0.4500-0.52%
Post-market: 85.850.00000.00%16:41 EST
Volume:43.95K
Turnover:3.77M
Market Cap:908.89M
PE:6.58
High:86.54
Open:85.21
Low:84.19
Close:86.30
52wk High:94.10
52wk Low:49.26
Shares:10.59M
Float Shares:5.93M
Volume Ratio:1.03
T/O Rate:0.74%
Dividend:0.72
Dividend Rate:0.84%
EPS(TTM):13.04
EPS(LYR):13.04
ROE:16.71%
ROA:2.36%
PB:0.99
PE(LYR):6.58

Loading ...

Electrovaya (ELVA) Gets a Buy from Oppenheimer

TIPRANKS
·
Feb 14

International Flavors & Fragrances Poised for Volume-Driven Recovery, Oppenheimer Says

MT Newswires Live
·
Feb 14

TE Connectivity Poised to Gain From AI, Automotive Growth, Oppenheimer Says

MT Newswires Live
·
Feb 14

Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says

MT Newswires Live
·
Feb 14

Oppenheimer Adjusts SharkNinja PT to $145 From $140, Maintains Outperform Rating

MT Newswires Live
·
Feb 13

Oppenheimer Adjusts TE Connectivity PT to $285 From $270, Maintains Outperform Rating

MT Newswires Live
·
Feb 13

Oppenheimer Adjusts BridgeBio Pharma Price Target to $83 From $81, Maintains Outperform Rating

MT Newswires Live
·
Feb 13

Oppenheimer Keeps Their Buy Rating on Waste Connections (WCN)

TIPRANKS
·
Feb 13

Oppenheimer Reaffirms Their Buy Rating on Toast Inc (TOST)

TIPRANKS
·
Feb 13

Oppenheimer Sticks to Their Buy Rating for Maplebear (CART)

TIPRANKS
·
Feb 13

BridgeBio price target raised to $83 from $81 at Oppenheimer

TIPRANKS
·
Feb 13

Oppenheimer Keeps Their Hold Rating on CVS Health (CVS)

TIPRANKS
·
Feb 13

Evommune Raises $125 Million in Private Placement of Common Stock

Reuters
·
Feb 13

Cadence Design Gets 'Warning' Shot, Oppenheimer Says

MT Newswires Live
·
Feb 13

Ascendis Pharma Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Feb 13

Inspire Medical Systems Lowers FY2026 Revenue Guidance After CMS Coding Clarification, Oppenheimer Says

MT Newswires Live
·
Feb 13

Oppenheimer Adjusts Pure Storage Price Target to $100 From $120, Maintains Outperform Rating

MT Newswires Live
·
Feb 12

Oppenheimer Adjusts Unity Software Price Target to $32 From $38, Maintains Outperform Rating

MT Newswires Live
·
Feb 12

Oppenheimer Adjusts Ascendis Pharma Price Target to $262 From $246, Maintains Outperform Rating

MT Newswires Live
·
Feb 12

Oppenheimer Adjusts Humana Price Target to $250 From $310, Maintains Outperform Rating

MT Newswires Live
·
Feb 12